«While expanding beta cell mass may still be desirable for
future diabetes therapy, improving the local environment of the otherwise healthy aged beta cell could prevent age - associated deterioration in glucose homeostasis and thereby promote healthy ageing, which is conceptually novel and highly exciting,» says Per - Olof Berggren.
«A clinical trial in both type 1 and type 2 diabetics in the immediate foreseeable
future is quite realistic, given the impressive nature of the reversal of the
diabetes, along with the feasibility in patients to do AAV gene
therapy.»